Drugs / PF-03732010
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00557505 | Dec 2007 → Feb 2011 | neoplasm | Pfizer | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-03732010 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00557505 ↗ |
| Known as | P-cadherin antagonist pf-03732010 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109534 ↗ |
| Action | Inhibit | “PF-03732010 is a new drug that inhibits P-cadherin.” NCT00557505 ↗1“Cadherin-3 inhibitor” CHEMBL2109534 ↗ |
| Route | Intravenous | “IV infusion.” NCT00557505 ↗ |
| Target | CDH3 | “Cadherin-3 inhibitor” CHEMBL2109534 ↗ |